Brucella spp. Lumazine Synthase induces a TLR4-mediated protective response against B16 melanoma in mice

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Rossi, Andrés H ^a   Farias, Ana ^a   Fernández, Javier E ^a   Bonomi, Hernán R ^a   Goldbaum, Fernando A ^a   Berguer, Paula M ^a  

^a FUNDACIÓN INSTITUTO LELOIR   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BRUCELLA LUMAZINE SYNTHASE; MELANOMA VACCINE; OVALBUMIN; PROTEIN MD 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; 6,7-DIMETHYL-8-RIBITYLLUMAZINE SYNTHASE; HYBRID PROTEIN; MULTIENZYME COMPLEX; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; MELANOMA B16; MELANOMA CELL; MOUSE; NONHUMAN; SURVIVAL RATE; ALLOTRANSPLANTATION; ANIMAL; APOPTOSIS; BIOSYNTHESIS; BRUCELLA; C57BL MOUSE; CD8+ T LYMPHOCYTE; CYTOLOGY; DEFICIENCY; ENZYMOLOGY; GENETICS; IMMUNOLOGY; MELANOMA, EXPERIMENTAL; METABOLISM; MORTALITY; PATHOLOGY; TUMOR CELL LINE;

BRUCELLA; MUS;

ANIMALS; APOPTOSIS; BRUCELLA; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MULTIENZYME COMPLEXES; OVALBUMIN; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; SURVIVAL RATE; TOLL-LIKE RECEPTOR 4; TRANSPLANTATION, HOMOLOGOUS;

EID: 84929359108     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126827     Document Type: Article

References (83)

1. Schreibelt G, Tel J, Sliepen KH, Benitez-Ribas D, Figdor CG, Adema GJ, et al. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer immunology, immunotherapy: CII. 2010; 59(10):1573-82. Epub 2010/03/06. doi: 10.1007/s00262-010-0833-1 PMID: 20204387.
2. Medzhitov R. Toll-like receptors and innate immunity. Nature reviews Immunology. 2001; 1(2):135-45. Epub 2002/03/22. doi: 10.1038/35100529 PMID: 11905821.
3. Asprodites N, Zheng L, Geng D, Velasco-Gonzalez C, Sanchez-Perez L, Davila E. Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2008; 22(10):3628-37. Epub 2008/07/01. doi: 10.1096/fj.08-108274 PMID: 18587008; PubMed Central PMCID: PMC2537425.
4. Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy. 2009; 1(6):949-64. Epub 2010/06/22. doi: 10.2217/imt.09.70 PMID: 20563267; PubMed Central PMCID: PMC2886992.
5. Furumoto K, Soares L, Engleman EG, Merad M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. The Journal of clinical investigation. 2004; 113(5):774-83. Epub 2004/03/03. doi: 10.1172/JCI19762 PMID: 14991076; PubMed Central PMCID: PMC351319.
6. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature. 2011; 470(7335):543-7. Epub 2011/02/26. doi: 10.1038/nature09737 PMID: 21350488; PubMed Central PMCID: PMC3057367.
7. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature medicine. 2007; 13(9):1050-9. Epub 2007/08/21. doi: 10.1038/nm1622 PMID: 17704786.
8. Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, et al. Toll-like receptors in tumor immunotherapy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007; 13(18 Pt 1):5280-9. Epub 2007/09/19. doi: 10.1158/1078-0432.CCR-07-1378 PMID: 17875756; PubMed Central PMCID: PMC2131730.
9. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. The Iowa orthopaedic journal. 2006; 26:154-8. Epub 2006/06/23. PMID: 16789469; PubMed Central PMCID: PMC1888599.
10. Thotathil Z, Jameson MB. Early experience with novel immunomodulators for cancer treatment. Expert opinion on investigational drugs. 2007; 16(9):1391-403. Epub 2007/08/24. doi: 10.1517/13543784.16.9.1391 PMID: 17714025.
11. Liu H, Komai-Koma M, Xu D, Liew FY. Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(18):7048-53. Epub 2006/04/25. doi: 10.1073/pnas.0601554103 PMID: 16632602; PubMed Central PMCID: PMC1444884.
12. Sutmuller RP, den Brok MH, Kramer M, Bennink EJ, Toonen LW, Kullberg BJ, et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. The Journal of clinical investigation. 2006; 116(2):485-94. Epub 2006/01/21. doi: 10.1172/JCI25439 PMID: 16424940; PubMed Central PMCID: PMC1332026.
13. Kabelitz D. Expression and function of Toll-like receptors in T lymphocytes. Current opinion in immunology. 2007; 19(1):39-45. Epub 2006/11/30. doi: 10.1016/j.coi.2006.11.007 PMID: 17129718.
14. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer research. 2005; 65(12):5009-14. Epub 2005/06/17. doi: 10.1158/0008-5472.CAN-05-0784 PMID: 15958541.
15. Sato Y, Goto Y, Narita N, Hoon DS. Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment. Cancer microenvironment: official journal of the International Cancer Microenvironment Society. 2009; 2 Suppl 1:205-14. Epub 2009/08/18. doi: 10.1007/s12307-009-0022-y PMID: 19685283; PubMed Central PMCID: PMC2756339.
16. Gonzalez-Reyes S, Marin L, Gonzalez L, Gonzalez LO, del Casar JM, Lamelas ML, et al. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC cancer. 2010; 10:665. Epub 2010/12/07. doi: 10.1186/1471-2407-10-665 PMID: 21129170; PubMed Central PMCID: PMC3009680.
17. Tewari R, Choudhury SR, Ghosh S, Mehta VS, Sen E. Involvement of TNFalpha-induced TLR4-NF-kappaB and TLR4-HIF-1alpha feed-forward loops in the regulation of inflammatory responses in glioma. J Mol Med (Berl). 2012; 90(1):67-80. Epub 2011/09/03. doi: 10.1007/s00109-011-0807-6 PMID: 21887505.
18. Park HD, Lee Y, Oh YK, Jung JG, Park YW, Myung K, et al. Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation. Oncogene. 2011; 30(2):201-11. Epub 2010/08/31. doi: 10.1038/onc.2010.401 PMID: 20802527; PubMed Central PMCID: PMC3399130.
19. Sheyhidin I, Nabi G, Hasim A, Zhang RP, Ainiwaer J, Ma H, et al. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World journal of gastroenterology: WJG. 2011; 17(32):3745-51. Epub 2011/10/13. doi: 10.3748/wjg.v17.i32.3745 PMID: 21990957; PubMed Central PMCID: PMC3181461.
20. Starska K, Forma E, Lewy-Trenda I, Stasikowska O, Brys M, Krajewska WM, et al. The expression of SOCS1 and TLR4-NFkappaB pathway molecules in neoplastic cells as potential biomarker for the aggressive tumor phenotype in laryngeal carcinoma. Folia histochemica et cytobiologica / Polish Academy of Sciences, Polish Histochemical and Cytochemical Society. 2009; 47(3):401-10. Epub 2010/02/19. doi: 10.2478/v10042-009-0075-2 PMID: 20164024.
21. Wang EL, Qian ZR, Nakasono M, Tanahashi T, Yoshimoto K, Bando Y, et al. High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. British journal of cancer. 2010; 102(5):908-15. Epub 2010/02/11. doi: 10.1038/sj.bjc.6605558 PMID: 20145615; PubMed Central PMCID: PMC2833250.
22. Earl TM, Nicoud IB, Pierce JM, Wright JP, Majoras NE, Rubin JE, et al. Silencing of TLR4 decreases liver tumor burden in a murine model of colorectal metastasis and hepatic steatosis. Annals of surgical oncology. 2009; 16(4):1043-50. Epub 2009/01/24. doi: 10.1245/s10434-009-0325-8 PMID: 19165543.
23. Eiro N, Ovies C, Fernandez-Garcia B, Alvarez-Cuesta CC, Gonzalez L, Gonzalez LO, et al. Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma: relationship with clinicopathological characteristics and prognosis. Archives of dermatological research. 2013; 305(1):59-67. Epub 2012/11/28. doi: 10.1007/s00403-012-1300-y PMID: 23179584.
24. Jego G, Bataille R, Geffroy-Luseau A, Descamps G, Pellat-Deceunynck C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia. 2006; 20(6):1130-7. Epub 2006/04/22. doi: 10.1038/sj.leu.2404226 PMID: 16628189.
25. Yoo KH, Lim TJ, Chang SG. Monthly intravesical bacillus Calmette-Guerin maintenance therapy for non-muscle-invasive bladder cancer: 10-year experience in a single institute. Experimental and therapeutic medicine. 2012; 3(2):221-5. Epub 2012/09/13. doi: 10.3892/etm.2011.400 PMID: 22969872; PubMed Central PMCID: PMC3438621.
26. Tsuji S, Matsumoto M, Takeuchi O, Akira S, Azuma I, Hayashi A, et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors. Infection and immunity. 2000; 68(12):6883-90. Epub 2000/11/18. PMID: 11083809; PubMed Central PMCID: PMC97794.
27. Roux S, Apetoh L, Chalmin F, Ladoire S, Mignot G, Puig PE, et al. CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. The Journal of clinical investigation. 2008; 118(11):3751-61. Epub 2008/10/03. doi: 10.1172/JCI35890 PMID: 18830416; PubMed Central PMCID: PMC2556241.
28. Panelli MC, Stashower ME, Slade HB, Smith K, Norwood C, Abati A, et al. Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome biology. 2007; 8(1):R8. Epub 2007/01/16. doi: 10.1186/gb-2007-8-1-r8 PMID: 17222352; PubMed Central PMCID: PMC1839129.
29. Urosevic M, Dummer R, Conrad C, Beyeler M, Laine E, Burg G, et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. Journal of the National Cancer Institute. 2005; 97(15):1143-53. Epub 2005/08/04. doi: 10.1093/jnci/dji207 PMID: 16077073.
30. Tillman DK Jr., Carroll MT. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience. Cutis. 2007; 79(3):241-8. Epub 2007/08/07. PMID: 17674590.
31. Braden BC, Velikovsky CA, Cauerhff AA, Polikarpov I, Goldbaum FA. Divergence in macromolecular assembly: X-ray crystallographic structure analysis of lumazine synthase from Brucella abortus. Journal of molecular biology. 2000; 297(5):1031-6. Epub 2000/04/15. doi: 10.1006/jmbi.2000.3640 PMID: 10764570.
32. Zylberman V, Craig PO, Klinke S, Braden BC, Cauerhff A, Goldbaum FA. High order quaternary arrangement confers increased structural stability to Brucella sp. lumazine synthase. The Journal of biological chemistry. 2004; 279(9):8093-101. Epub 2003/12/09. doi: 10.1074/jbc.M312035200 PMID: 14660615.
33. Laplagne DA, Zylberman V, Ainciart N, Steward MW, Sciutto E, Fossati CA, et al. Engineering of a polymeric bacterial protein as a scaffold for the multiple display of peptides. Proteins. 2004; 57(4):820-8. Epub 2004/09/25. doi: 10.1002/prot.20248 PMID: 15390265.
34. Sciutto E, Toledo A, Cruz C, Rosas G, Meneses G, Laplagne D, et al. Brucella spp. lumazine synthase: a novel antigen delivery system. Vaccine. 2005; 23(21):2784-90. Epub 2005/03/23. doi: 10.1016/j.vaccine.2004.11.043 PMID: 15780726.
35. Craig PO, Berguer PM, Ainciart N, Zylberman V, Thomas MG, Martinez Tosar LJ, et al. Multiple display of a protein domain on a bacterial polymeric scaffold. Proteins. 2005; 61(4):1089-100. Epub 2005/09/30. doi: 10.1002/prot.20635 PMID: 16193482.
36. Rosas G, Fragoso G, Ainciart N, Esquivel-Guadarrama F, Santana A, Bobes RJ, et al. Brucella spp. lumazine synthase: a novel adjuvant and antigen delivery system to effectively induce oral immunity. Microbes and infection / Institut Pasteur. 2006; 8(5):1277-86. Epub 2006/05/16. doi: 10.1016/j.micinf.2005.12.006 PMID: 16697684.
37. Berguer PM, Mundinano J, Piazzon I, Goldbaum FA. A polymeric bacterial protein activates dendritic cells via TLR4. J Immunol. 2006; 176(4):2366-72. Epub 2006/02/04. PMID: 16455994.
38. Berguer PM, Alzogaray VA, Rossi AH, Mundinano J, Piazzon I, Goldbaum FA. A polymeric protein induces specific cytotoxicity in a TLR4 dependent manner in the absence of adjuvants. PloS one. 2012; 7 (9):e45705. Epub 2012/10/03. doi: 10.1371/journal.pone.0045705 PMID: 23029192; PubMed Central PMCID: PMC3454435.
39. Fidler IJ, Darnell JH, Budmen MB. Tumoricidal properties of mouse macrophages activated with mediators from rat lymphocytes stimulated with concanavalin A. Cancer research. 1976; 36(10):3608-15. Epub 1976/10/01. PMID: 953987.
40. Fidler IJ, Nicolson GL. Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. Journal of the National Cancer Institute. 1976; 57(5):1199-202. Epub 1976/11/01. PMID: 1003551.
41. Bellone M, Cantarella D, Castiglioni P, Crosti MC, Ronchetti A, Moro M, et al. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J Immunol. 2000; 165(5):2651-6. Epub 2000/08/18. PMID: 10946294.
42. Dennis LK. Analysis of the melanoma epidemic, both apparent and real: data from the 1973 through 1994 surveillance, epidemiology, and end results program registry. Archives of dermatology. 1999; 135(3):275-80. Epub 1999/03/23. PMID: 10086448.
43. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2001; 19(16):3622-34. Epub 2001/08/16. PMID: 11504744.
44. Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, et al. An evidence-based staging system for cutaneous melanoma. CA: a cancer journal for clinicians. 2004; 54(3):131-49; quiz 82-4. Epub 2004/06/16. PMID: 15195788.
45. Del Prete SA, Maurer LH, O'Donnell J, Forcier RJ, LeMarbre P. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer treatment reports. 1984; 68(11):1403-5. Epub 1984/11/01. PMID: 6541973.
46. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1999; 17(9):2745-51. Epub 1999/11/24. PMID: 10561349.
47. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2000; 18(1):158-66. Epub 2000/01/07. PMID: 10623706.
48. Tawbi HA, Kirkwood JM. Management of metastatic melanoma. Seminars in oncology. 2007; 34(6):532-45. Epub 2007/12/18. doi: 10.1053/j.seminoncol.2007.09.008 PMID: 18083377.
49. Legha SS. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Seminars in oncology. 1997; 24(1 Suppl 4):S39-43. Epub 1997/02/01. PMID: 9122733.
50. Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A, Urban A, Schell H, Hohenberger W, et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. International journal of radiation oncology, biology, physics. 1999; 44(3):607-18. Epub 1999/05/29. PMID: 10348291.
51. Anderson CM, Buzaid AC, Legha SS. Systemic treatments for advanced cutaneous melanoma. Oncology (Williston Park). 1995; 9(11):1149-58; discussion 63-4, 67-8. Epub 1995/11/01. PMID: 8703684.
52. Curti BD, Urba WJ. Clinical deployment of antibodies for treatment of melanoma. Molecular immunology. 2015. Epub 2015/03/10. doi: 10.1016/j.molimm.2015.01.025 PMID: 25746916.
53. Weiss SA, Chandra S, Pavlick AC. Update on vaccines for high-risk melanoma. Current treatment options in oncology. 2014; 15(2):269-80. Epub 2014/05/03. doi: 10.1007/s11864-014-0283-7 PMID: 24788575.
54. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. The New England journal of medicine. 2010; 363(9):809-19. Epub 2010/09/08. doi: 10.1056/NEJMoa1002011 PMID: 20818844; PubMed Central PMCID: PMC3724529.
55. Arkenau HT, Kefford R, Long GV. Targeting BRAF for patients with melanoma. British journal of cancer. 2011; 104(3):392-8. Epub 2010/12/09. doi: 10.1038/sj.bjc.6606030 PMID: 21139585; PubMed Central PMCID: PMC3049553.
56. Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, et al. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PloS one. 2011; 6(12):e28973. Epub 2011/12/24. doi: 10.1371/journal.pone.0028973 PMID: 22194965; PubMed Central PMCID: PMC3237573.
57. Slominski A, Paus R, Mihm MC. Inhibition of melanogenesis as an adjuvant strategy in the treatment of melanotic melanomas: selective review and hypothesis. Anticancer research. 1998; 18(5B):3709-15. Epub 1998/12/17. PMID: 9854482.
58. Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiological reviews. 2004; 84(4):1155-228. Epub 2004/09/24. doi: 10.1152/physrev.00044.2003 PMID: 15383650.
59. Slominski A, Zmijewski MA, Pawelek J. L-tyrosine and L-dihydroxyphenylalanine as hormone-like regulators of melanocyte functions. Pigment cell & melanoma research. 2012; 25(1):14-27. Epub 2011/08/13. doi: 10.1111/j.1755-148X.2011.00898.x PMID: 21834848; PubMed Central PMCID: PMC3242935.
60. Brozyna AA, Jozwicki W, Carlson JA, Slominski AT. Melanogenesis affects overall and disease-free survival in patients with stage III and IV melanoma. Human pathology. 2013; 44(10):2071-4. Epub 2013/06/25. doi: 10.1016/j.humpath.2013.02.022 PMID: 23791398; PubMed Central PMCID: PMC3783651.
61. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity. 2008; 29(3):372-83. Epub 2008/09/19. doi: 10.1016/j.immuni.2008.08.004 PMID: 18799145.
62. Palucka K, Ueno H, Fay J, Banchereau J. Harnessing dendritic cells to generate cancer vaccines. Annals of the New York Academy of Sciences. 2009; 1174:88-98. Epub 2009/09/23. doi: 10.1111/j.1749-6632.2009.05000.x PMID: 19769741; PubMed Central PMCID: PMC2759270.
63. von Euw EM, Barrio MM, Furman D, Levy EM, Bianchini M, Peguillet I, et al. A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10-1082 promoter genotype as predictor of disease progression. Journal of translational medicine. 2008; 6:6. Epub 2008/01/29. doi: 10.1186/1479-5876-6-6 PMID: 18221542; PubMed Central PMCID: PMC2265680.
64. Mac Keon S, Gazzaniga S, Mallerman J, Bravo AI, Mordoh J, Wainstok R. Vaccination with dendritic cells charged with apoptotic/necrotic B16 melanoma induces the formation of subcutaneous lymphoid tissue. Vaccine. 2010; 28(51):8162-8. Epub 2010/10/13. doi: 10.1016/j.vaccine.2010.09.095 PMID: 20937314.
65. Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J, Wainstok R. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J Immunol. 2003; 171(11):5940-7. Epub 2003/11/25. PMID: 14634105.
66. Goldbaum FA, Velikovsky CA, Baldi PC, Mortl S, Bacher A, Fossati CA. The 18-kDa cytoplasmic protein of Brucella species-an antigen useful for diagnosis-is a lumazine synthase. Journal of medical microbiology. 1999; 48(9):833-9. Epub 1999/09/11. PMID: 10482294.
67. Andreani V, Gatti G, Simonella L, Rivero V, Maccioni M. Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer research. 2007; 67(21):10519-27. Epub 2007/11/03. doi: 10.1158/0008-5472.CAN-07-0079 PMID: 17974996.
68. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol. 2006; 176(8):4894-901. Epub 2006/04/06. PMID: 16585585.
69. Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, Wang JM. Toll-like receptors in inflammation, infection and cancer. International immunopharmacology. 2007; 7(10):1271-85. Epub 2007/08/04. doi: 10.1016/j.intimp.2007.05.016 PMID: 17673142.
70. Krieg AM. Development of TLR9 agonists for cancer therapy. The Journal of clinical investigation. 2007; 117(5):1184-94. Epub 2007/05/04. doi: 10.1172/JCI31414 PMID: 17476348; PubMed Central PMCID: PMC1857270.
71. Kumar H, Kawai T, Akira S. Pathogen recognition in the innate immune response. The Biochemical journal. 2009; 420(1):1-16. Epub 2009/04/23. doi: 10.1042/BJ20090272 PMID: 19382893.
72. Tsan MF. Toll-like receptors, inflammation and cancer. Seminars in cancer biology. 2006; 16(1):32-7. Epub 2005/09/13. doi: 10.1016/j.semcancer.2005.07.004 PMID: 16153858.
73. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nature medicine. 2007; 13(5):552-9. Epub 2007/05/05. doi: 10.1038/nm1589 PMID: 17479101.
74. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene. 2008; 27(2):218-24. Epub 2008/01/08. doi: 10.1038/sj.onc.1210904 PMID: 18176603.
75. Sautes-Fridman C, Cherfils-Vicini J, Damotte D, Fisson S, Fridman WH, Cremer I, et al. Tumor microenvironment is multifaceted. Cancer metastasis reviews. 2011; 30(1):13-25. Epub 2011/01/29. doi: 10.1007/s10555-011-9279-y PMID: 21271351.
76. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine. 2010; 363(8):711-23. Epub 2010/06/08. doi: 10.1056/NEJMoa1003466 PMID: 20525992; PubMed Central PMCID: PMC3549297.
77. Spagnolo F, Queirolo P. Upcoming strategies for the treatment of metastatic melanoma. Archives of dermatological research. 2012; 304(3):177-84. Epub 2012/02/22. doi: 10.1007/s00403-012-1223-7 PMID: 22350184.
78. Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, et al. Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. The Journal of experimental medicine. 2013; 210(9):1685-93. Epub 2013/07/31. doi: 10.1084/jem.20130573 PMID: 23897982; PubMed Central PMCID: PMC3754864.
79. Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer immunology research. 2013; 1(1):32-42. Epub 2014/04/30. doi: 10.1158/2326-6066.CIR-13-0013 PMID: 24777248.
80. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. The Journal of experimental medicine. 2013; 210(9):1695-710. Epub 2013/07/31. doi: 10.1084/jem.20130579 PMID: 23897981; PubMed Central PMCID: PMC3754863.
81. Nunez NG, Andreani V, Crespo MI, Nocera DA, Breser ML, Moron G, et al. IFNbeta produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response. Cancer research. 2012; 72(3):592-603. Epub 2011/12/06. doi: 10.1158/0008-5472.CAN-11-0534 PMID: 22139376.
82. Brozyna AA, VanMiddlesworth L, Slominski AT. Inhibition of melanogenesis as a radiation sensitizer for melanoma therapy. International journal of cancer Journal international du cancer. 2008; 123(6):1448-56. Epub 2008/06/21. doi: 10.1002/ijc.23664 PMID: 18567001.
83. Slominski A, Kim TK, Brozyna AA, Janjetovic Z, Brooks DL, Schwab LP, et al. The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1alpha expression and HIF-dependent attendant pathways. Archives of biochemistry and biophysics. 2014; 563:79-93. Epub 2014/07/06. doi: 10.1016/j.abb.2014.06.030 PMID: 24997364; PubMed Central PMCID: PMC4221528.